Inlybest — Axitinib 5 mg
Inlybest is an oral targeted therapy medication for advanced kidney cancer. Active ingredient: Axitinib (5 mg).
Manufacturer: Cipla (India). It is a generic version of Inlyta, classified as a Tyrosine Kinase Inhibitor (TKI).
How it works (Starving the tumor):
Inlybest works by inhibiting Vascular Endothelial Growth Factor Receptors (VEGFR). Essentially, it stops the tumor from growing new blood vessels (angiogenesis). Without a blood supply to bring oxygen and nutrients, the tumor shrinks or stops growing.
✅ Key Benefit: Specifically designed for patients who have not responded to previous systemic treatments.
Indicated for the treatment of Advanced Renal Cell Carcinoma (RCC).
It is used as a second-line therapy after failure of one prior systemic therapy (such as Sunitinib or cytokines).
- Uncontrolled Hypertension: Dangerously high blood pressure.
- Severe hepatic impairment (Child-Pugh Class C).
- Recent history of arterial thromboembolic events (stroke, heart attack) or severe bleeding within the last 12 months.
- Pregnancy and breastfeeding.
- Uncontrolled Hypertension: Dangerously high blood pressure.
- Severe hepatic impairment (Child-Pugh Class C).
- Recent history of arterial thromboembolic events (stroke, heart attack) or severe bleeding within the last 12 months.
- Pregnancy and breastfeeding.
The most common side effect is Hypertension (High Blood Pressure). Daily monitoring is required.
Other common reactions:
- Diarrhea: Stay hydrated and use anti-diarrheal meds if needed.
- Hand-Foot Syndrome: Redness, swelling, or pain on the palms of hands and soles of feet.
- Fatigue: Feeling weak or tired.
- Dysphonia: Hoarseness of voice.
What Customers Say
No reviews yet
Your review can be the first!